Patients who received Tagrisso had a longer period (18.9 months) without cancer progression versus 10.2 months with Iressa (gefitinib) or Tarceva (erlotinib). Among the patients who
responded to treatment, the average duration of response was 17.6 months with Tagrisso versus 9.6 months with Iressa or Tarceva.
The most common side effects with Tagrisso are diarrhea, rash, dry skin, and decreased appetite.
